InteKrin Provides Phase 2a Results For Diabetes Drug

InteKrin has declared Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans. The study demonstrated that once a day oral treatment with INT131 provides anti-diabetic efficacy, consistent with maximal dose thiazolidinedione (TZD) therapy with less hematocrit reduction and weight gain.

The 4 week double blind placebo controlled study of INT131 in Type 2 Diabetes Mellitus patients showed a dose dependent decrease in fasting plasma glucose (FPG).

The efficacy measured at 4 weeks of 1mg of INT131 treatment was comparable to the efficacy modeled for this patient population treated with the maximal approved doses of Actos and Avandia.

Alex DePaoli, CMO of InteKrin, said: These data are supportive of INT131 acting as a selective modulator of PPARgamma in T2DM patients.

The key observation from this study is that INT131 is a potent insulin sensitizer that lowers fasting glucose as well as the maximal dose of the TZDs while mitigating the typical side effect profile, he added.